Impacts of Opioids on Respiratory Drive During Sleep (OIRD)

Mass General Brigham

Status and phase

Begins enrollment in 4 months

Early Phase 1

Conditions

Obstructive Sleep Apnea (OSA)

Opioids

Treatments

Drug: Placebo

Drug: Morphine p.o.

Study type

Interventional

Funder types

Other

Identifiers

NCT06854211

2024P002115

Details and patient eligibility

About

The investigators are studying the impact that opioids have on breathing during sleep in healthy participants and those diagnosed with obstructive sleep apnea.

Enrollment

26 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy controls: Apnea Hypopnea Index (AHI) < 5 events/hr on in-laboratory PSG within 3 months of enrollment
OSA group: AHI > 10 events/hr on in-laboratory PSG within 3 months of enrollment; treated or untreated.

Exclusion criteria

Sleep disordered breathing or respiratory disorders (other than OSA in the OSA group), such as central sleep apnea (>50% of respiratory events scored as central), chronic hypoventilation/hypoxemia (awake SaO2 < 92% by oximetry) due to chronic obstructive pulmonary disease or other respiratory conditions.
Other sleep disorders: periodic limb movements (periodic limb movement index > 20/hr), narcolepsy, or parasomnias.
Any unstable major medical condition.
Medications expected to stimulate or depress respiration (including other opioids taken at home, barbiturates, benzodiazepines, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid).
History of allergy to lidocaine or oxymetazoline.
Contraindications for morphine, including:
allergy to morphine or opioids
chronic obstructive pulmonary disease, asthma, or other significant respiratory disorders
kidney or liver dysfunction, as this can affect the metabolism and excretion of morphine, leading to increased risk of toxicity.
women who are pregnant or breastfeeding will be excluded due to potential risks to the fetus or infant.
history of substance abuse, particularly opioid abuse, will be excluded to prevent potential misuse or relapse.
current use of central nervous system depressants.
individuals with gastrointestinal obstruction. Constipation is not an exclusion criterion because morphine is only administered for one night.
recent head injury, brain tumors, or other conditions leading to increased intracranial pressure.
unstable heart disease, particularly those with risk factors for or a history of heart rhythm disorders.
epilepsy or a history of seizures, as morphine can lower the seizure threshold.
severe psychiatric conditions, particularly those with a history of psychosis, as opioids can exacerbate these conditions.
medications that interact with morphine, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), Monoamine oxidase inhibitors (MAOIs), and the atypical antidepressants buproprion and trazodone.
untreated or unstable endocrine disorders like adrenal insufficiency or thyroid dysfunction.